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Introduction the Review Group on Peripheral Vascular Diseases.
This strategy included handsearching of relevant med-
The following abstracts are part of an ongoing quar- ical journals and extensive MEDLINE searches. In
addition, trials were identified by cross-referencingterly series of articles produced by the Cochrane Col-
laborative Review Group on Peripheral Vascular published work, by direct contact with principal in-
vestigators of trials, and by EMBASE searches.Diseases. The reviews are published in full on the
Cochrane Library, a quarterly electronic journal avail-
Selection Criteriaable on CD ROM and on the World Wide Web. This
format allows Cochrane reviews to accommodate new All randomised controlled trials of an exercise regimen
versus control, or versus medical or surgical therapy,data as it becomes available, making the library a
consistently up to date source of information over in patients with intermittent claudication due to ath-
erosclerotic disease were included. The exercise re-time.
If you are interested in preparing a Cochrane review, gimen was not specified, and inclusion of trials was
not affected by the duration, frequency or intensity ofor becoming a member of the Peripheral Vascular
Diseases Group please contact: the exercise programme. Possible trials were identified
by GCL, and their eligibility for inclusion in the reviewProfessor F. G. R. Fowkes, Cochrane Collaborative
checked by EE.Review Group on Peripheral Vascular Disease,
Department of Public Health Sciences, University of
Data Collection and AnalysisEdinburgh, Teviot Place, Edinburgh EH8 9AG, U.K.
Fourteen trials were identified which met the inclusion
criteria, but five were subsequently excluded because
of poor quality. The remaining nine trials involved a
Abstracts total of just over 200 patients. Five trials compared
exercise with an untreated control group (three used
Abstract: Exercise for Intermittent Claudication placebo tablets), two compared exercise with inter-
G.C. Leng, B. Fowler and E. Ernst vention (surgery and angioplasty), and two small trials
Date of most recent substantive amendment: 9 April 1998 used drug regimens as the control (antiplatelets and
pentoxifylline). The exercise regimens varied, but all
Objective recommended at least two sessions weekly. All trials
To determine whether in patients with intermittent used a treadmill walking test as one of the outcome
claudication, an exercise programme was effective in measures, six included calf blood flow, and four the
alleviating symptoms and increasing walking distance. ankle brachial pressure index (ABPI). Continuous data
Secondary objectives were to determine whether ex- were analysed by weighted mean differences, using
ercise was effective in preventing deterioration of both the fixed effect and random effects models.
underlying disease and reducing cardiovascular
events. Main Results
Exercise therapy significantly improved maximal
Search Strategy walking distance (OR 6.51, 95% CI 4.36, 8.66), with an
All publications describing randomised controlled tri- overall improvement in walking ability of ap-
als of exercise therapy in intermittent claudication proximately 150% (range 74%–230%). Exercise pro-
duced significant improvements in walking distancewere sought using the search strategy described by
1078–5884/99/010003+02 $12.00/0 Ó 1999 W.B. Saunders Company Ltd.
Cochrane Review Group4
compared with angioplasty at 6 months (OR 2.17, 95% and one or more of the following outcomes had to be
assessed: subjective perception of pain, disability, andCI 1.31, 3.03) and antiplatelet therapy (OR 1.06, 95%
walking distance (assessed by the patient and/or byCI 0.15, 1.97), but did not differ significantly from
the doctor), ankle-arm pressure index, walking dis-surgical treatment. In one small trial, exercise was less
tance until onset of pain on standard treadmill, totaleffective than pentoxifylline (OR-0.45, 95% CI-0.66,
walking distance on standard treadmill, occurrence of-0.24). Exercise did not have a significant effect on
vascular surgery, amputation and death.the ABPI or calf blood flow, and these outcomes were
similar after angioplasty or antiplatelet therapy. The
Data Collection and AnalysisABPI was significantly improved following surgery,
All assessments and extraction of data were performedhowever (OR -0.27, 95% CI -0.37, -0.17), but there
unblinded by both authors independently before dis-was a higher rate of adverse events (18%) and deaths
cussion to resolve disagreements.experienced by those undergoing surgery.
For each included trial, information was extracted
about the characteristics of the patients, the allocationConclusions
procedure, number of drop-outs, the exact dosage ofExercise is of significant benefit to patients with in-
the intervention compounds and control treatments,termittent claudication, and therefore should be re-
double-blinding, outcomes, methods of the analysescommended to all suitable patients. However, further
and conclusions of the authors.studies are required to determine the longer term
The results of the included randomised clinical trialsbenefits of exercise compared with other treatments
would have been assessed in a primary analysis, how-such as surgery and pentoxifylline, and to evaluate
ever, as only one trial described its randomisationthe cost-effectiveness of different exercise regimens.
procedure in sufficient detail, a secondary analysis
only was done.Abstract: Vitamin E for the Treatment of Intermittent
Claudication
Main ResultsJ. Kleijnen and D. Mackerras
The five controlled trials included in the review lastedDate of most recent substantive amendment: 5 January
between 12 weeks and 18 months, measured four1998
different physical outcomes, and used five different
doses of vitamin E. All trials showed positive effectsObjective
on one of their main outcomes. Two trials lastedTo assess evidence of the efficacy of vitamin E on approximately 8 months, used similar doses, and both
subjective and objective outcomes, including per- reported patients’ subjective evaluation of the treat-
ception of pain, disability, walking distance, ankle- ment. These results have been pooled and indicate a
arm blood pressure index, walking distance until onset favourable effect. The pooled relative risk was 0.6
of pain on a standard treadmill, and the occurrence with a 95% confidence interval that crossed 1 when a
of vascular surgery, amputation or death, in patients random effects model analysis was done.
with intermittent claudication, for trials with a follow-
up period of at least three months. Conclusions
We do not think there is enough data to recommend
Search Strategy using vitamin E for patients with intermittent clau-
All reports of randomised clinical trials or controlled dication. Furthermore, no trials comparing the effects
clinical trials of vitamin E in intermittent claudication of vitamin E to other possible treatments were found,
were sought using the search strategy adopted by so it was not possible to put the positive trends dis-
the Cochrane Review Group on Peripheral Vascular played in most trials into perspective. Given that, to
Diseases. date, no serious side effects have been reported, and
that synthetic vitamin E is very cheap, some people
Selection Criteria might consider it worthwhile trying. We would re-
Controlled and/or randomised clinical trials using commend a bigger randomised trial, especially to com-
vitamin E in at least one group were identified for pare vitamin E against both a placebo and another
two levels of analysis. Patients were required to have treatment, and to include a range of subjective and
objective outcome measures.intermittent claudication with well-defined disease,
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